Physician profile
Cheryl W Mcginnis
NPI 1184831463
$1,973.23
in general payments reported to CMS, 2019-2025
13 companies · $890 in 2025
The $890 reported for 2025 was less than what a typical Transplantation provider received nationally (typical 2025 total: $890).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $204 · 2023: $467 · 2024: $298 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $364.61 | 2022-2025 | Watchman Flx, Watchman Access System |
| Neurocrine Biosciences, INC. | $243.91 | 2024-2025 | Ingrezza |
| Regeneron Healthcare Solutions, INC. | $227.84 | 2025 | Dupixent, Evkeeza |
| Astrazeneca Pharmaceuticals Lp | $172.93 | 2023 | Farxiga, Lokelma |
| Pulmonx Corporation | $147.10 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Beone Medicines USA, INC. | $124.93 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $118.86 | 2025 | Besremi |
| Zoll Respicardia, INC. | $114.86 | 2021 | |
| Janssen Scientific Affairs, LLC | $105.90 | 2024 | Tremfya |
| Genentech USA, INC. | $92.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $91.39 | 2023 | Givlaari |
| Genzyme Corporation | $90.96 | 2023 | |
| Amgen INC. | $77.06 | 2024 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Mcginnis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.